KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $105.4 billion.

  • AbbVie's Non-Current Assets fell 888.82% to $105.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $431.3 billion, marking a year-over-year decrease of 94.63%. This contributed to the annual value of $109.6 billion for FY2024, which is 773.78% up from last year.
  • As of Q3 2025, AbbVie's Non-Current Assets stood at $105.4 billion, which was down 888.82% from $107.9 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Non-Current Assets ranged from a high of $123.9 billion in Q1 2021 and a low of $101.7 billion during Q4 2023
  • Its 5-year average for Non-Current Assets is $111.6 billion, with a median of $110.0 billion in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 21422.12% in 2021, then crashed by 888.82% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Non-Current Assets stood at $118.6 billion in 2021, then dropped by 6.96% to $110.3 billion in 2022, then dropped by 7.82% to $101.7 billion in 2023, then grew by 7.74% to $109.6 billion in 2024, then dropped by 3.85% to $105.4 billion in 2025.
  • Its Non-Current Assets stands at $105.4 billion for Q3 2025, versus $107.9 billion for Q2 2025 and $108.5 billion for Q1 2025.